Inhibition of Eif4e with Ribavirin Cooperates with Common Chemotherapies in Primary Acute Myeloid Leukemia Specimens

Total Page:16

File Type:pdf, Size:1020Kb

Inhibition of Eif4e with Ribavirin Cooperates with Common Chemotherapies in Primary Acute Myeloid Leukemia Specimens Letters to the Editor 1197 Acknowledgements patient subgroup characterized by very poor prognosis. J Clin Oncol 1989; 7: 119–125. This study is supported in part by the grants CA 62242, CA 107476 3 San Miguel JF, Garcia-Sanz R, Gonzalez M, Moro MJ, Hernandez JM, and CA 62242 from the National Cancer Institute, National Ortega F et al. A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood 1995; 85: Institutes of Health, Bethesda, MD and the Eastern Cooperative 448–455. Oncology Group, Boston, MA (SVR). 4 Rajkumar SV, Fonseca R, Dewald GW, Therneau TM, Lacy MQ, Kyle RA et al. Cytogenetic abnormalities correlate with the plasma P Kapoor1, S Kumar1, SJ Mandrekar2, KM Laumann2, 1 1 1 1 cell labeling index and extent of bone marrow involvement in A Dispenzieri , MQ Lacy , D Dingli , MA Gertz , myeloma. Cancer Genet Cytogenet 1999; 113: 73–77. 1 1 1 1 RA Kyle , PR Greipp , SV Rajkumar and TE Witzig 5 Garcia-Sanz R, Gonzalez-Fraile MI, Mateo G, Hernandez JM, 1 Division of Hematology, Mayo Clinic, Lopez-Berges MC, de las Heras N et al. Proliferative activity of Rochester, MN, USA and plasma cells is the most relevant prognostic factor in elderly 2Division of Biomedical Statistics and Informatics, multiple myeloma patients. Int J Cancer 2004; 112: 884–889. Mayo Clinic, Rochester, MN, USA 6 Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Geyer S, E-mail: [email protected] Kabat B et al. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexametha- sone in newly diagnosed myeloma. Mayo Clin Proc 2007; 82: 1179–1184. References 7 Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR et al. Combination therapy with thalidomide plus 1 Greipp PR, Lust JA, O’Fallon WM, Katzmann JA, Witzig TE, Kyle RA. dexamethasone for newly diagnosed myeloma. J Clin Oncol Plasma cell labeling index and beta 2-microglobulin predict survival 2002; 20: 4319–4323. independent of thymidine kinase and C-reactive protein in multiple 8 Kapoor P, Kumar S, Fonseca R, Lacy MQ, Witzig TE, Hayman SR myeloma. Blood 1993; 81: 3382–3387. et al. Impact of risk stratification on outcome among patients with 2 Boccadoro M, Marmont F, Tribalto M, Fossati G, Redoglia V, multiple myeloma receiving initial therapy with lenalidomide and Battaglio S et al. Early responder myeloma: kinetic studies identify a dexamethasone. Blood 2009; 114: 518–521. Inhibition of eIF4E with ribavirin cooperates with common chemotherapies in primary acute myeloid leukemia specimens Leukemia (2011) 25, 1197–1200; doi:10.1038/leu.2011.57; In preclinical studies, it was shown that M4/M5 AML published online 1 April 2011 specimens were more sensitive to ribavirin than normal controls or M1/M2 AML specimens with normal eIF4E levels.6 This strongly suggests that cells with elevated eIF4E have developed an oncogene addiction to this protein.2,6 Acute myeloid leukemia (AML) is the most common type of acute In a Phase II trial, ribavirin monotherapy led to clinical leukemia in adults and it is associated with poor outcomes. Typical responses including remissions in poor prognosis M4 and M5 induction strategies involve treatment with cytarabine (Ara-C) AML patients.7 Further, molecular studies showed that ribavirin along with an anthracycline, either idarubicin or daunorubicin, inhibited eIF4E activity in patients.7 Importantly, there was no andisreferredtoas7þ 3 therapy.1 This strategy can result in an therapy-related toxicity observed in these patients.7 These approximately 70% complete remission rate, but of these, about clinical studies suggested that ribavirin could be a new tool 70% will relapse.1 Further confounding the difficulty in inducing for AML treatment. Thus, we set out to investigate whether remissions is the morbidity associated with this treatment regimen. ribavirin treatment enhances the activity of anti-cancer agents Many patients over the age of 60, who are the majority of AML commonly used in the treatment of AML, including Ara-C, patients, cannot tolerate this treatment modality.1 Thus, it is idarubicin, sorafenib and azacytidine. imperative to develop novel strategies to treat AML. The effects of drug combinations were assessed using primary The eukaryotic translation initiation factor eIF4E is over- specimens from AML patients (obtained from the BCLQ tissue expressed in many cancers, including the M4 and M5 FAB bank with ethics committee approval) or healthy volunteers 2,3 subtypes of AML. Elevated eIF4E levels are generally correlated (Supplementary Table 1). We examined whether 1 mM ribavirin 2,3 with poor prognosis in these cancers. eIF4E affects gene expres- potentiated the effects of Ara-C (0.5 nM), idarubicin (0.3 nM)or sion post-transcriptionally by enhancing the mRNA export and/or Ara-C þ idarubicin, using colony growth assays in methylcellu- translation of specific growth promoting transcripts.2–5 Both of lose. Results from AML specimens derived from seven indivi- these activities contribute to the oncogenic potential of eIF4E and duals diagnosed with M4/M5 AML were assessed and these both require the ability of eIF4E to associate with the 50 7-methyl results are amalgamated in Table 1. Although both ribavirin and guanosine cap (m7G) structure found on mRNAs.4,5 Ara-C alone reduced colony number to about 40% of the Ribavirin acts as a competitive inhibitor of the cap, thereby untreated samples, the combination further reduced colonies to inhibiting the mRNA export and translation functions of about 20%. Similarly, idarubicin alone slightly reduced colony eIF4E.2,6 The ability of ribavirin to directly bind eIF4E and number to about 80%, but in combination with ribavirin to inhibit cap binding is based on a battery of biochemical studies 20–30%. Idarubicin with Ara-C reduced colony numbers to including NMR, mass spectrometry, fluorescence, cap chromato- about 20–30%, with the exception of the M4 AML Flt3-WT graphy and 3H ribavirin eIF4E immunoprecipitation.2,6 specimen (see below). Strikingly, the triple combination Leukemia Letters to the Editor 1198 Table 1 Effects of drugs on colony formation of primary AML specimens Drug AML-M4 AML-M4 AML-M5 AML-M5 AML-M1 AML-M1 AML-M2 Normal Normal FLT3 MUT FLT3 WT FLT3 MUT FLT3 WT High 4E PBMC CD34+ %Av±s.d. %Av ± s.d. %Av±s.d. %Av±s.d. %Av±s.d. %Av±s.d. %Av±s.d. %Av±s.d. %Av±s.d. Untreated 100±8a 100±10 100±9b 100±8 100±7 100±8 100±3 100±12a 100±3 Rib 41±8a 41±548±6b 53±445±477±569±580±14a 87±3 Ara-C 49±5a 63±12 39±7b 42±454±559±971±568±11b 82±3 Ara-C+Rib 18±3a 20±726±9b 17±719±453±753±575±8b 70±5 Ida 70±6a 99±13 75±6b 76±684±492±584±386±10a 94±3 Ida+Rib 19±3a 16±10 34±6b 33±529±475±679±362±10a 88±5 Ida+Ara-C 24±3a 60±723±4b 20±421±456±664±363±13b 82±3 Ida+Ara-C+Rib 10±3a 7±513±36±214±247±656±661±10b 74±4 Sor 50±955±10 64±7b 57±667±478±11 70±11 77±5NA Sor+Rib 21±416±323±4b 31±425±365±11 73±362±7NA Aza 77±778±963±867±677±572±478±360±766±7 Aza+Rib 30±67±432±524±628±559±767±349±570±3 Abbreviations: Av, average as a percent of the relevant untreated control; FLT3 MUT, specimens with internal tandem duplication; FLT3 WT, no mutation detected; NA, not available; s.d., standard deviation. Specimens are treated as described in the materials and methods. All experiments were carried out in replicates of five and repeated at least three independent times. Drug abbreviations and dosages were as follows: Rib ¼ ribavirin (1 mM), Ara-C ¼ cytarabine (0.5 nM), Ida ¼ idarubicin (0.3 nM), Sor ¼ sorafenib (2 mM), Aza ¼ azacytidine (3 mM). Note that cross comparison indicated that there was no correlation between NPM status and ribavirin dependent colony inhibition consistent with results in the clinical trial.6 aIndicates results amalgamated from three specimens. bIndicates results amalgamated from two specimens. (ribavirin/Ara-C/idarubicin) reduced colonies to 5–10% in all (Supplementary Table 2), modestly reduced colony number (to M4/M5 specimens examined. The triple combination, at these 70%) in M4/M5 and M1 high-4E specimens (Table 1). The concentrations, only slightly affected specimens from healthy addition of ribavirin strikingly reduced this (to 10–30%). M1/M2 volunteers (Table 1, Supplementary Table 2). specimens, or those from healthy volunteers, were sensitive to Our studies show that ribavirin was active in both Flt3 wild treatment with azacytidine (60–70%), but ribavirin did not type and mutant specimens (Table 1), reducing colony numbers substantially augment this. Thus, M4/M5 AML and M1-high4E to about 40% for both Flt3 mutant and wild-type specimens in specimens are more sensitive to the azacytidine-ribavirin the M4 or M5 setting. This suggests, in this limited number of combination than the other groups. specimens, that ribavirin sensitivity is independent of Flt3 status, Our studies indicate that a wide variety of agents cooperate as we observed in our Phase II clinical trial. The only major with ribavirin to reduce colony growth. Thus, we examined difference observed in this context was the lack of sensitivity of the effects of these agents on eIF4E activity in primary AML the M4 AML Flt3-WT for idarubicin alone, or combined with specimens treated for 48 h. We confirmed that ribavirin targeted Ara-C.
Recommended publications
  • A Catalogue of the Fellows, Candidates, Licentiates [And Extra
    MDCCCXXXVI. / Od- CATALOGUE OF THE FELLOWS, CANDIDATES, AND LICENTIATES, OF THE ftogal College of LONDON. STREET. PRINTED 1!Y G. WGOUFAM., ANGEL COURT, SKINNER A CATALOGUE OF THE FELLOWS, CANDIDATES, AND LICENTIATES, OF THE Ittojjal College of ^ijpstrtans, LONDON. FELLOWS. Sir Henry Halford, Bart., M.D., G.C.IL, President, Physician to their Majesties , Curzon-street . Devereux Mytton, M.D., Garth . John Latham, M.D., Bradwall-hall, Cheshire. Edward Roberts, M.D. George Paulet Morris, M.D., Prince s-court, St. James s-park. William Heberden, M.D., Elect, Pall Mall. Algernon Frampton, M.D., Elect, New Broad- street. Devey Fearon, M.D. Samuel Holland, M.D. James Franck, M.D., Bertford-street. Park- lane. Sir George Smith Gibbes, Knt., M.D. William Lambe, M.D., Elect, Kings-road, Bedford-row. John Johnstone, M.D., Birmingham. Sir James Fellowes, Knt., M.D., Brighton. Charles Price, M.D., Brighton. a 2 . 4 Thomas Turner, M.D., Elect, and Trea- Extraordinary to surer, Physician the Queen , Curzon-street Edward Nathaniel Bancroft, M.D., Jamaica. Charles Dalston Nevinson, M.D., Montagu- square. Robert Bree, M.D., Elect, Park-square , Regent’s-park. John Cooke, M.D., Gower-street Sir Arthur Brooke Faulkner, Knt., M.D., Cheltenham. Thomas Hume, M.D., Elect, South-street , Grosvenor-square. Peter Rainier, M.D., Albany. Tristram Whitter, M.D. Clement Hue, M.D., Elect, Guildford- street. John Bright, M.D., Manchester-square. James Cholmeley, M.D., Bridge-street Henry , Blackfriars. Sir Thomas Charles Morgan, Knt., M.D., Dublin. Richard Simmons, M.D. Joseph Ager, M.D., Great Portland-st.
    [Show full text]
  • Transactions
    M,EDICO - CHIRURGICAL TRANSACTIONS, PIUBLISHED BY THE ROYAL MEDICAL AND CHIRURGICAL SOCIETY OF It{en LONDON. VOLUME THE THIRTY-FIRST. LONDON: PRINTED FOR LONGMAN, BROWN, GREEN, AND LONGMANS, PATERNOSTER-ROW. 1848. RICtARDIOUERT , AILNTER, GREE.N ARtIlUB CO1URT, OLD IBAILEY, LOqDON. MEDICO - CHIRURGICAI TRANSACTIONS, PUBLISHED BY THE ROYAL MEDICAL AND CHIRURGICAL SOCIETY OF LONDON. SECOND SERIES. VOLUME THE THIRTEENTH. LONDON: PRJNTED POR LONGMAN, BROWN, GREEN AND LONGMANS, PATERNOSTER-ROW. 1848. RICHARD KINDER, PRINTER, GREEN ARHOUR COURT, OLD BAILEY, LONDON. ROYAL MEDICAL AND CHIRURGICAL SOCIETY OF LONDON. PATRON, THE QUEEN. OFFICERS AND COUNCIL, ELECTED MARCH 1, 1848. PRESIDENT. JAMES MONCRIEFF ARNOTT, F.R.S. rHENRY DAVIES, M.D. JONATHAN M.D., F.R.S. VICE-PRESIDENTS.<V PEREIRA, GEORGE MACILWAIN. LRICHARD PARTRIDGE, F.R.S. { BENJAMIN GUY BABINGTON, M.D., F.R.S. TREASURERS. BENJAMIN PHILLIPS, F.R.S. f WILLIAM BALY, M.D., F.R.S. SECRETARIES. FRED. LE GROS CLARK. { JOHN HENNEN, M.D. LIBRARIANS. l_RICHARD QUAIN, F.R.S. JAMES ALDERSON, M.D., F.R.S. THOMAS MAYO, M.D., F.R.S. ROBERT NAIRNE, M.D. WILLIAM SHARPEY, M.D., F.R.S. OTHER MEMBERS LEONARD STEWART, M.D. OF THE COUNCIL. HENRY ANCELL RICHARD BLAGDEN. GEORGE BUSK. JOHN DALRYMPLE. JAMES PAGET. TRUSTEES OF THE SOCIETY. JAMES M. ARNOTT, F.R.S. JOHN CLENDINNING, M.D., F.R.S. EDWARD STANLEY, F.R.S. a2 FELLOWS OF THE SOCIETY APPOINTED BY THE COUNCIL AS REFEREES OF PAPERS, FOR THE SESSION OF 1847-8. BABINGTON, BENJAMIN G., M.D., F.R.S. BOWMAN, WILLIAM, F.RIS. BUDD, GEORGE, M.D., F.R.S.
    [Show full text]
  • Chipman Family a Genealogy Of
    THE CHIPMAN FAMILY A GENEALOGY OF THE CHIPMANS IN AMERICA 1631-1920 BY BERT LEE CHIPMAN BERT L. CHIPMAN. PUBLISHER WINSTON-SALEM. N. C. COPYRIGHT 1920 BERT L. CHIPMAN MONOTYPED BY THE WINSTON PRINTING COMPANY WrN9TON-SALEM, N. C, Introduction Many hours have been spent in gathering and compiling the data that makes up this genealogy of the Chipman family; a correspondence has been carried on extending to every part of the United States and Canada, requiring several thousand letters; but it has been a pleasant task. What is proposed by genealogical research is not to laud individuals, nor to glorify such families as would other­ wise remain without glory. Heraldic arms have as little worth as military aside from the worth of those bearing them. Not the armor but the army merits and should best repay describing. It has been my earnest desire to make this work as complete and accurate as possible. In this connection I wish to acknowledge the valuable aid in research work rendered by Mr. W. A. Chipman (1788), Mr. S. L. Chip­ man (1959), Mrs. B. W. Gillespie (see 753) and Mrs. Margaret T. Reger (see 920). C Orgin THE NAME CHIPMAN is of English otjgin, early existing in various forms such as,-Chipenham, Chippenham, Chiepman and Chipnam. The name is to be found quite frequently in the books prepared by the Record Commis­ sion appointed by the British Parliament, and from i085 to 1350 it usually appears with the prefix de, as,~e Chippenham. Several towns in England bear the name in one of its f onns, for instance: Chippenham, Buckingham Co., twenty-two miles from London, is "a Liberty in the Parish and Hundred of Burnham, forming a part of the ancient demesnes of the crown and said to be the site of a palace of the Mercian kings." Chippenham, Cambridge Co., sixty-one miles from London, is '' a Parish in the Hundred of Staplehou, a dis­ charged Vicarage in the Archdeaconry of Suffolk and Diocese of Norwich." Chippenham, Wilts Co., ninety-three miles from London, is "a Borough, Market-town and Parish in the Hundred of Chippenham and a place of great antiquity.
    [Show full text]
  • Subject Categories
    Subject Categories Click on a Subject Category below: Anthropology Archaeology Astronomy and Astrophysics Atmospheric Sciences and Oceanography Biochemistry and Molecular Biology Business and Finance Cellular and Developmental Biology and Genetics Chemistry Communications, Journalism, Editing, and Publishing Computer Sciences and Technology Economics Educational, Scientific, Cultural, and Philanthropic Administration (Nongovernmental) Engineering and Technology Geology and Mineralogy Geophysics, Geography, and Other Earth Sciences History Law and Jurisprudence Literary Scholarship and Criticism and Language Literature (Creative Writing) Mathematics and Statistics Medicine and Health Microbiology and Immunology Natural History and Ecology; Evolutionary and Population Biology Neurosciences, Cognitive Sciences, and Behavioral Biology Performing Arts and Music – Criticism and Practice Philosophy Physics Physiology and Pharmacology Plant Sciences Political Science / International Relations Psychology / Education Public Affairs, Administration, and Policy (Governmental and Intergovernmental) Sociology / Demography Theology and Ministerial Practice Visual Arts, Art History, and Architecture Zoology Subject Categories of the American Academy of Arts & Sciences, 1780–2019 Das, Veena Gellner, Ernest Andre Leach, Edmund Ronald Anthropology Davis, Allison (William Gluckman, Max (Herman Leakey, Mary Douglas Allison) Max) Nicol Adams, Robert Descola, Philippe Goddard, Pliny Earle Leakey, Richard Erskine McCormick DeVore, Irven (Boyd Goodenough, Ward Hunt Frere Adler-Lomnitz, Larissa Irven) Goody, John Rankine Lee, Richard Borshay Appadurai, Arjun Dillehay, Tom D. Grayson, Donald K. LeVine, Robert Alan Bailey, Frederick George Dixon, Roland Burrage Greenberg, Joseph Levi-Strauss, Claude Barth, Fredrik Dodge, Ernest Stanley Harold Levy, Robert Isaac Bateson, Gregory Donnan, Christopher B. Greenhouse, Carol J. Levy, Thomas Evan Beall, Cynthia M. Douglas, Mary Margaret Grove, David C. Lewis, Oscar Benedict, Ruth Fulton Du Bois, Cora Alice Gumperz, John J.
    [Show full text]
  • 2018 Program May 21-24, 2018 | Pittsburgh, Pa Pathologyinformatics.Org
    DIGITAL PATHOLOGY REALIZED 2018 PROGRAM MAY 21-24, 2018 | PITTSBURGH, PA PATHOLOGYINFORMATICS.ORG Brought to you by the Association for Pathology Informatics. Greetings and welcome to all of you. Thank you for joining us! The Pathology Informatics Summit 2018 is the 28th sequential year of a “...over 40 combined years of conference legacy resulting from the merger of two long-standing and successful previous conference excellence in Pathology Informatics series: APIII and Lab InfoTech Summit/AIMCL. All together, these two prior meetings, along with the instruction and scholarly exchange PI-Summit series, have offered over 40 combined years of excellence in Pathology Informatics instruction and for the pathology specialty.” scholarly exchange for the pathology specialty. Over these four decades, our specialty has witnessed a progressive succession from coverage of the Refreshment and lunch breaks will provide you with ample time to browse the exhibitor ballroom, fundamentals of computing and information technology, to increasingly sophisticated exemplars with displays by 23 exhibitors with IT-related products and services. This represents one of the where cogent use of information technology can be seen to greatly enhance both patient safety as largest assemblages of pathology informatics vendors available at any conference in the country. well and the diagnostic and predictive utility of the primary data generated by the collective fields We guarantee that you will gain a host of new ideas and solutions from all of these resources. of Anatomic Pathology and Laboratory Medicine. In consonance with the continuing evolution of the specialty, this year is particularly auspicious in that several watershed events—FDA clearance of All of the faculty PowerPoint lectures, along with synchronized audio, will be posted on the whole slide imaging for primary diagnosis, and the explosive growth in understanding of the utility conference website (PathologyInformatics.org) shortly after the conference adjournment.
    [Show full text]
  • Medical Videography Using a Mobile App: Retrospective Analysis
    JMIR MHEALTH AND UHEALTH Cambron et al Original Paper Medical Videography Using a Mobile App: Retrospective Analysis Julia C Cambron1, BS; Kirk D Wyatt2, MD; Christine M Lohse3, MS; Page Y Underwood4, JD; Thomas R Hellmich5, MD 1Mayo Clinic Alix School of Medicine, Mayo Clinic, Rochester, MN, United States 2Division of Pediatric Hematology/Oncology, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, United States 3Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, United States 4Legal Department, Mayo Clinic, Scottsdale, AZ, United States 5Department of Emergency Medicine, Mayo Clinic, Rochester, MN, United States Corresponding Author: Thomas R Hellmich, MD Department of Emergency Medicine Mayo Clinic 200 First Street Southwest Rochester, MN, 55905 United States Phone: 1 507 255 2216 Email: [email protected] Abstract Background: As mobile devices and apps grow in popularity, they are increasingly being used by health care providers to aid clinical care. At our institution, we developed and implemented a point-of-care clinical photography app that also permitted the capture of video recordings; however, the clinical findings it was used to capture and the outcomes that resulted following video recording were unclear. Objective: The study aimed to assess the use of a mobile clinical video recording app at our institution and its impact on clinical care. Methods: A single reviewer retrospectively reviewed video recordings captured between April 2016 and July 2017, associated metadata, and patient records. Results: We identified 362 video recordings that were eligible for inclusion. Most video recordings (54.1%; 190/351) were captured by attending physicians. Specialties recording a high number of video recordings included orthopedic surgery (33.7%; 122/362), neurology (21.3%; 77/362), and ophthalmology (15.2%; 55/362).
    [Show full text]
  • The Supreme Court's Myriad Effects on Scientific Research
    THE SUPREME COURT’S MYRIAD EFFECTS ON SCIENTIFIC RESEARCH: DEFINITIONAL FLUIDITY AND THE LEGAL CONSTRUCTION OF NATURE Peter Lee UC Davis School of Law Contents INTRODUCTION .................................................................................................................... 1 PART I. THE IMPACT ON MYRIAD GENETICS AND BRCA RESEARCH ............................... 3 PART II. UPSTREAM-DOWNSTREAM DYNAMICS IN PATENT LAW ..................................... 9 PART III. BROADER DOCTRINAL IMPLICATIONS ............................................................. 19 A. Elevating Patentable Subject Matter Doctrine to Police Patentability .................. 19 B. Creating a Strong and Flexible Exception for Nature from Patent Eligibility ...... 20 PART IV. ONGOING CHALLENGES AND LONG-TERM RAMIFICATIONS ............................ 28 CONCLUSION ...................................................................................................................... 31 INTRODUCTION Although patent law rarely captures the popular imagination, such was not the case in the summer of 2013. That June, the Supreme Court issued its much-anticipated decision in Association for Molecular Pathology v. Myriad Genetics.1 The decision culminated years of litigation over several patents held by Myriad Genetics, a Utah-based biotechnology company, covering two genes, BRCA 1 and BRCA 2. Mutations in these genes are correlated with a higher risk of developing breast and ovarian cancer. Based significantly on its patents, Myriad Genetics enjoyed exclusive
    [Show full text]
  • List of the Fellows and Members
    \ / ^' ^CVR C'i AN S- i .m vS^. fe# Itifos^ ^i^F^-SJffi" p MDCCCXX XI. A CATALOGUE OP THE FELLOWS, CANDIDATES, » AND . LICENTIATES, OP THE LONDON. PRINTEI> BY G. WOODFALL, ANGEL COURT, SKINNER STREET. /T^ o ^ A CATALOGUi: OF THE FELLOWS, CANDIDATES, AND LICENTIATES, OF THE 3aopal College of ^i)}mtinm, LONDON. FELLOWS. Sir Henry Halford, Bart. G.C.H. President, Physician to their Majesties, Curzon-street. Dr. Devereux Mytton, Garth. Dr. John Latham, Bradwall-HalU Cheshire. Dr. Thomas Monro. Dr. Wilham Moore, Isle of Wight. Dr. Edward Roberts, Elect, JB/oo?w56^^r^-S5'^^are. Dr. George Paulet Morris. Dr. Henry Ainslie, Dover-street. Dr. Paggen Wilham Mayo, Bridlington. Dr. Richard Powell. Dr. William Heberden, Fall Mall. Dr. Algernon Frampton, Elect, New Broad-st. Dr. George Williams, Oxford. Dr. Devey Fearon. Dr. Samuel Holland. Dr. Wilham George Maton, Elect, Physician Extraordinary to the King, New-street, Spring Gardens. Dr. James Franck, Hertford-street, Park-lane, Sir George Smith Gibbes, Knt. Bath. Dr. William Lambe, Elect, Kings-road, Bedford-row. 2 Dr. John Johnstone, Birmingham. Sir James Fellowes, Knt. Dr. Charles Price, Brighton. Dr. Thomas Turner, Elect, and Treasurer, Physician Extraordinary to the Queen, Cur- zon-street. Dr. Edward Nathaniel Bancroft, Jamaica, Dr. Charles Dalston Nevinson, Montague-square, Dr. Pelham Warren, Elect, Lower Brook-st, Dr. Robert Bree, Elect, George-street, Hanover-square Dr. John Cooke, Gower-street. Sir Arthur Brooke Faulkner, Knt. Cheltenham, Dr. Thomas Hume, Censor, South-street, Grosvenor-square Dr. Peter Rainier, Albany, Dr. Tristram Whitter. Dr. Clement Hue, Guildford-street. Dr. John Bright, Manchester-square, Dr.
    [Show full text]
  • 2012 MVSS Historical Book
    Midwestern Vascular Surgical Society Historical Book THE MEDICAL COLLEGE OF WISCONSIN The Historical Book is dedicated to John R. Pfeifer, M.D., Historian Midwestern Vascular Surgical Society 2012 2012 MIDWESTERN VASCULAR SURGICAL SOCIETY TABLE OF Contents Page Executive Council/Committees ..................................................................3 Acknowledgments .....................................................................................7 Annual Meetings and Dates .......................................................................8 Presidents of the Midwestern Vascular Surgical Society ............................ 11 Names and Addresses of Presidents .......................................................... 87 Officers of the Society............................................................................. 88 History of the Midwestern Vascular Surgical Society ................................. 89 John R. Pfeifer Award ............................................................................ 106 Charles C. Guthrie Award ...................................................................... 107 The D. Emerick Szilagyi Award .............................................................. 113 Web Page History .................................................................................. 115 Distinguished Service Award ................................................................. 134 Constitution and By-Laws of the Society ................................................ 135 New Members Elected ..........................................................................
    [Show full text]
  • Characterization of a Pathogenic Variant in the ABCD1 Gene Through Protein Molecular Modeling
    Hindawi Case Reports in Genetics Volume 2020, Article ID 3256539, 7 pages https://doi.org/10.1155/2020/3256539 Case Report Characterization of a Pathogenic Variant in the ABCD1 Gene Through Protein Molecular Modeling John E. Richter Jr.,1 Charitha Vadlamudi,2 Sarah K. Macklin,1 Ayesha Samreen,3 Haytham Helmi,1 Daniel Broderick,4 Ahmed N. Mohammad,1 Stephanie L. Hines,5 Jay A. VanGerpen,6 Paldeep S. Atwal ,1 and Thomas R. Caulfield 1,7,8,9,10 1Department of Clinical Genomics, Mayo Clinic, Jacksonville, FL 32224, USA 2Department of Pulmonology, Mayo Clinic, Jacksonville, FL 32224, USA 3Department of Endocrinology, Mayo Clinic, Jacksonville, FL 32224, USA 4Department of Radiology, Mayo Clinic, Jacksonville, FL 32224, USA 5Department of Internal Medicine, Mayo Clinic, Jacksonville, FL 32224, USA 6Department of Neurology, Mayo Clinic, Jacksonville, FL 32224, USA 7Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA 8Department of Cancer Biology, Mayo Clinic, Jacksonville, FL 32224, USA 9Department of Neurosurgery, Mayo Clinic, Jacksonville, FL 32224, USA 10Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL 32224, USA Correspondence should be addressed to omas R. Caulfield; caulfi[email protected] Received 15 August 2019; Accepted 19 November 2019; Published 25 January 2020 Academic Editor: Yoshiyuki Ban Copyright © 2020 John E. Richter Jr. et al. is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background. e ATP-binding cassette, subfamily D, member 1 (ABCD1) protein is a peroxisomal half-transporter that allows for very long chain fatty acid (VLCFA) degradation.
    [Show full text]
  • Case Report Curing Opioid Toxicity with Intrathecal Targeted Drug Delivery
    Hindawi Case Reports in Medicine Volume 2019, Article ID 3428576, 6 pages https://doi.org/10.1155/2019/3428576 Case Report Curing Opioid Toxicity with Intrathecal Targeted Drug Delivery Thomas P. Pittelkow ,1,2 Markus A. Bendel ,1 Jacob J. Strand,2 and Susan M. Moeschler1 1Division of Pain Medicine, Department of Anesthesiology and Perioperative Medicine, Mayo Clinic College of Medicine and Science, 200 First Street SW, Rochester, MN 55905, USA 2Center for Palliative Medicine, Department of Medicine, Mayo Clinic College of Medicine and Science, 200 First Street SW, Rochester, MN 55905, USA Correspondence should be addressed to omas P. Pittelkow; [email protected] Received 30 January 2019; Revised 16 April 2019; Accepted 2 May 2019; Published 16 May 2019 Academic Editor: Piotr K. Janicki Copyright © 2019 omas P. Pittelkow et al. is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Pain is one of the most feared symptoms that concern cancer patients and their families. Despite well-established guidelines set forth by the World Health Organization (WHO) on the treatment of cancer pain, nearly half of cancer patients report poorly controlled pain. One of the most serious side effects of systemic oral opioid use is neurotoxicity, which is characterized by altered mental status and systemic neurologic impairments. Treatment strategies are supportive in nature and focused on reducing or changing the offending opioid and correcting any metabolic deficiencies. Herein, we discuss a case of opioid-induced neuro- toxicity treated with intrathecal targeted drug delivery (TDD).
    [Show full text]
  • Medical and Chirurgical Society
    MEDICO-CHIRURGICAL TRANSACTIONS. PUBLISHED BY v THE ROYAL MEDICAL AND CHIRURGICAL SOCIETY OF LONDON. VOLUME THE FORTY-FOURTH. LONDON: LONGMAN, GREEN, LONGMAN, AND ROBERTS, PATERNOSTER ROW. 1861. MEDICO-CHEIRIJRGIC. TRANSACTIONS. PUBLISHED BY THE ROYAL N MEDICAL AND CHIRURGICAL SOCI OF LONDON. SECOND SERIES. VOLUME THE TWENTY-SIXTH. LONDON: LONGMAN, GREEN, LONGMAN, AND ROBERTS, PATERNOSTER ROW. 1861. PRINTED BY J. E. ADLARD, BARTHOLOMEW CLOSE. ADVERTISEMENT. THE Council of the Royal Medical and Chirurgical Society deems it proper to state, that the Society does not hold itself in any way responsible for the statements, reasonings, or opinions set forth in the various papers, which, on grounds of general merit, are thought worthy of being published in its Transactions. VOL. XLIV. a REGULATIONS relative to the publcation ofthe " Proceedings of the Society." That as a general rule, the Proceedings will be issued every two months, subject to variations dependent on the extent of matter to be printed. That a Copy of the Proceedings will be sent, postage free, to every Fellow of the Society resident in the United Kingdom. "The Proceedings of the Society" may be obtained by non-members at the Society's House, 53, Berners Street, on prepayment of an annual subscription of five shillings, which may be transmitted either by post-office order or in postage stamps ;-this will include the expense of conveyance by post to any part of the United King- dom; to other places they will be sent, carriage free, through a bookseller, or by post, the receiver paying the foreign charges. That a notice of every paper will appear in the Proceedings.
    [Show full text]